S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Why This Bear Market Is Not Even Close to Being Done…
Sell every Stock except ONE (Ad)
Denmark says Nord Stream 1 pipelines stop leaking
Denmark says Nord Stream 1 natural gas pipeline has also stopped leaking
Sell every Stock except ONE (Ad)
Brazil holds historic election with Lula against Bolsonaro
US shift away from coal hits tribal community in New Mexico
A One Stop Shop for Everything Futures Trading (Ad)pixel
Tesla sales bounce back in Q3 but fall short of estimates
Voter apathy in Bulgaria opens door for pro-Russia groups
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Why This Bear Market Is Not Even Close to Being Done…
Sell every Stock except ONE (Ad)
Denmark says Nord Stream 1 pipelines stop leaking
Denmark says Nord Stream 1 natural gas pipeline has also stopped leaking
Sell every Stock except ONE (Ad)
Brazil holds historic election with Lula against Bolsonaro
US shift away from coal hits tribal community in New Mexico
A One Stop Shop for Everything Futures Trading (Ad)pixel
Tesla sales bounce back in Q3 but fall short of estimates
Voter apathy in Bulgaria opens door for pro-Russia groups
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Why This Bear Market Is Not Even Close to Being Done…
Sell every Stock except ONE (Ad)
Denmark says Nord Stream 1 pipelines stop leaking
Denmark says Nord Stream 1 natural gas pipeline has also stopped leaking
Sell every Stock except ONE (Ad)
Brazil holds historic election with Lula against Bolsonaro
US shift away from coal hits tribal community in New Mexico
A One Stop Shop for Everything Futures Trading (Ad)pixel
Tesla sales bounce back in Q3 but fall short of estimates
Voter apathy in Bulgaria opens door for pro-Russia groups
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Why This Bear Market Is Not Even Close to Being Done…
Sell every Stock except ONE (Ad)
Denmark says Nord Stream 1 pipelines stop leaking
Denmark says Nord Stream 1 natural gas pipeline has also stopped leaking
Sell every Stock except ONE (Ad)
Brazil holds historic election with Lula against Bolsonaro
US shift away from coal hits tribal community in New Mexico
A One Stop Shop for Everything Futures Trading (Ad)pixel
Tesla sales bounce back in Q3 but fall short of estimates
Voter apathy in Bulgaria opens door for pro-Russia groups
NYSE:BHVN

Biohaven Pharmaceutical - BHVN Stock Forecast, Price & News

$151.17
-0.36 (-0.24%)
(As of 09/30/2022 09:01 PM ET)
Add
Compare
Today's Range
$151.10
$151.90
50-Day Range
$145.99
$152.20
52-Week Range
$79.01
$152.56
Volume
1.94 million shs
Average Volume
1.06 million shs
Market Capitalization
$10.83 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$157.17

Biohaven Pharmaceutical MarketRank™ Forecast

Analyst Rating
Hold
2.25 Rating Score
Upside/​Downside
4.0% Upside
$157.17 Price Target
Short Interest
Bearish
7.18% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.14mentions of Biohaven Pharmaceutical in the last 14 days
Based on 9 Articles This Week
Insider Trading
Acquiring Shares
$5.63 M Bought Last Quarter
Proj. Earnings Growth
Growing
From ($13.82) to ($6.53) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.26 out of 5 stars

Medical Sector

1070th out of 1,095 stocks

Pharmaceutical Preparations Industry

533rd out of 547 stocks

BHVN stock logo

About Biohaven Pharmaceutical (NYSE:BHVN) Stock

Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavegepant that is in phase III clinical trials for acute and preventive treatment of migraine, as well as respiratory complications and non-migraine studies; and BHV-3100 for non-migraine indications. The company also offers Troriluzole for spinocerebellar ataxia and obsessive compulsive disorders, as well as Alzheimer diseases; BHV-0223, a product for amyotrophic lateral sclerosis; BHV-5000/5500 for neuropsychiatric indications; and Verdiperstat, a product for multiple system atrophy and amyotrophic lateral sclerosis. Biohaven Pharmaceutical Holding Company Ltd. has a collaboration agreement with Cove to facilitate telemedicine evaluation for migraine sufferers. The company was incorporated in 2013 and is headquartered in New Haven, Connecticut.

Receive BHVN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biohaven Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

BHVN Stock News Headlines

Biohaven's ALS drug fails to meet study goals
UPDATE 1-Biohaven's ALS drug fails to meet study goals
Biohaven Pharmaceutical (NYSE:BHVN) Sets New 1-Year High at $152.10
See More Headlines
Receive BHVN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biohaven Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

BHVN Company Calendar

Last Earnings
8/05/2022
Today
10/02/2022
Next Earnings (Estimated)
11/08/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Previous Symbol
NASDAQ:BHVN
Fax
N/A
Employees
928
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$157.17
High Stock Price Forecast
$177.00
Low Stock Price Forecast
$146.00
Forecasted Upside/Downside
+4.0%
Consensus Rating
Hold
Rating Score (0-4)
2.25
Research Coverage
8 Analysts

Profitability

Net Income
$-846,590,000.00
Net Margins
-108.04%
Pretax Margin
-105.78%

Debt

Sales & Book Value

Annual Sales
$462.51 million
Book Value
($11.34) per share

Miscellaneous

Free Float
62,761,000
Market Cap
$10.83 billion
Optionable
Optionable
Beta
1.04

Key Executives

  • Dr. Vladimir Coric M.D. (Age 51)
    Chairman, CEO & Pres
    Comp: $1.81M
  • Mr. Matthew Buten (Age 61)
    Chief Financial Officer
    Comp: $766.47k
  • Ms. Kimberly  GentileMs. Kimberly Gentile (Age 56)
    Sr. VP of Clinical Operations
    Comp: $1.03M
  • Dr. Elyse Stock M.D. (Age 63)
    Chief Medical Officer
    Comp: $1.15M
  • Mr. William Jones M.B.A. (Age 58)
    Chief Commercial Officer of Migraine & Common Diseases
    Comp: $1.04M
  • Mr. Matthew DeLawder
    Director of Accounting
  • Mr. George C. ClarkMr. George C. Clark (Age 38)
    VP & Chief Accounting Officer
  • Dr. Charles Conway Ph.D. (Age 60)
    Chief Scientific Officer
  • Ms. Wendy Goss
    Exec. Admin. Assistant
  • Mr. Clifford Bechtold M.S.
    Pres & GM of Biohaven Ireland and Chief Compliance Officer













BHVN Stock - Frequently Asked Questions

Should I buy or sell Biohaven Pharmaceutical stock right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Biohaven Pharmaceutical in the last twelve months. There are currently 6 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" BHVN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BHVN, but not buy additional shares or sell existing shares.
View BHVN analyst ratings
or view top-rated stocks.

What is Biohaven Pharmaceutical's stock price forecast for 2022?

8 equities research analysts have issued 1 year price objectives for Biohaven Pharmaceutical's shares. Their BHVN share price forecasts range from $146.00 to $177.00. On average, they expect the company's share price to reach $157.17 in the next twelve months. This suggests a possible upside of 4.0% from the stock's current price.
View analysts price targets for BHVN
or view top-rated stocks among Wall Street analysts.

How have BHVN shares performed in 2022?

Biohaven Pharmaceutical's stock was trading at $137.81 at the beginning of 2022. Since then, BHVN shares have increased by 9.7% and is now trading at $151.17.
View the best growth stocks for 2022 here
.

Are investors shorting Biohaven Pharmaceutical?

Biohaven Pharmaceutical saw a drop in short interest during the month of August. As of August 31st, there was short interest totaling 4,430,000 shares, a drop of 10.0% from the August 15th total of 4,920,000 shares. Based on an average daily volume of 661,600 shares, the short-interest ratio is presently 6.7 days. Currently, 7.1% of the company's stock are sold short.
View Biohaven Pharmaceutical's Short Interest
.

When is Biohaven Pharmaceutical's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 8th 2022.
View our BHVN earnings forecast
.

How were Biohaven Pharmaceutical's earnings last quarter?

Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) issued its quarterly earnings data on Friday, August, 5th. The company reported ($6.21) earnings per share for the quarter, missing the consensus estimate of ($2.79) by $3.42. The firm had revenue of $215.08 million for the quarter, compared to the consensus estimate of $209.33 million.

What other stocks do shareholders of Biohaven Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Biohaven Pharmaceutical investors own include AbbVie (ABBV), NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), Alibaba Group (BABA), ACADIA Pharmaceuticals (ACAD), QUALCOMM (QCOM), Pfizer (PFE), Sarepta Therapeutics (SRPT) and Abbott Laboratories (ABT).

When did Biohaven Pharmaceutical IPO?

(BHVN) raised $124 million in an initial public offering on Thursday, May 4th 2017. The company issued 8,300,000 shares at $14.00-$16.00 per share. Morgan Stanley, Piper Jaffray and Barclays Capital served as the underwriters for the IPO and William Blair and Needham & Company were co-managers.

What is Biohaven Pharmaceutical's stock symbol?

Biohaven Pharmaceutical trades on the New York Stock Exchange (NYSE) under the ticker symbol "BHVN."

How do I buy shares of Biohaven Pharmaceutical?

Shares of BHVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Biohaven Pharmaceutical's stock price today?

One share of BHVN stock can currently be purchased for approximately $151.17.

How much money does Biohaven Pharmaceutical make?

Biohaven Pharmaceutical (NYSE:BHVN) has a market capitalization of $10.83 billion and generates $462.51 million in revenue each year. The company earns $-846,590,000.00 in net income (profit) each year or ($14.82) on an earnings per share basis.

How many employees does Biohaven Pharmaceutical have?

The company employs 928 workers across the globe.

How can I contact Biohaven Pharmaceutical?

Biohaven Pharmaceutical's mailing address is 215 CHURCH STREET, NEW HAVEN CT, 06510. The official website for the company is www.biohavenpharma.com. The company can be reached via phone at (203) 404-0410 or via email at jennifer.porcelli@biohavenpharma.com.

This page (NYSE:BHVN) was last updated on 10/3/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.